Impact of Comorbid Conditions on Linaclotide Treatment Outcomes in Adults With CIC or IBS-C and Pediatric Patients With FC: A Post Hoc Analysis of Phase 3 Clinical Trial Data

Linzess (linaclotide) - Ironwood Pharma, AbbVie

https://acg2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=R01PT1FGR0UyNjkyNQ&PosterID=831198&rnd=0.6455166

Kyle Staller MD MPH 1; Christopher V. Almario MD MSHPM 2; Xiao Jing Wang MD 3; Morgan Sendzischew Shane MD 4; Linda Nguyen MD 5; Charlotte Dancey PhD 6; Sally Higgins PharmD 7; Annie Cheung PharmD 7; James Wu PhD 7

Aug 29, 2026